Lokelma (sodium zirconium cyclosilicate) is a small molecule pharmaceutical. Sodium zirconium cyclosilicate was first approved as Lokelma on 2018-03-22. It is used to treat hyperkalemia in the USA. It has been approved in Europe to treat hyperkalemia. Lokelma's patents are valid until 2035-10-14 (FDA).
|Common Name||Sodium zirconium cyclosilicate|
|Drug Class||Quaternary ammonium derivatives|